07:00 , Jun 20, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Endocrine/metabolic disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine/metabolic disease Diabetes Solute carrier family 10 sodium-dependent bile acid transporter member 2 (SLC10A2; ASBT; IBAT) In vitro and rodent studies identified benzothiazepine ASBT inhibitors that...